Eledon Pharmaceuticals shares rise 2.37% after-hours following updated Phase Ib data conference call.

Eledon Pharmaceuticals, Inc. rose 2.37% in after-hours trading, following the company's updated Phase Ib data conference call. The call, which was held to present new data, likely generated investor interest and optimism about the company's progress, leading to the stock's increase.